"GLP-1 medications are powerful tools, but they are not passive treatments, and patients who combine them with proper nutrition, strength training and medical oversight are more likely to achieve healthier and more sustainable outcomes," she said.
Kobori T, Onishi Y, Yoshida Y, Tahara T, Kikuchi T, Kubota T, et al
Many Hashimoto's patients find that moderate doses (0.5-1.0 mg semaglutide, 5-10 mg tirzepatide ) provide meaningful benefits without the gastrointestinal intensity of maximum doses
Lastly, type 3 and type 4 hypersensitivity results in the formation of antigenantibody immune complexes or a delayed T cell-mediated reaction, respectively, either of which may progress to the life-threatening Stevens-Johnson syndrome or toxic epidermal necrolysis [4, 5]